Zsírmáj (MASLD/MASH): ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• PPAR 1
• AMPK 0
• GLP-1 7
• SGLT2 5
• NRF2 1
• SIRT1 0
• PNPLA3 6
• NLRP3 1
• mTOR 0
• AKT 0
• PI3K 0
• STAT3 0
• TLR4 0
• MAPK 0
• STING 0
• JNK 0
• TP53 0
• PINK1 0
• TNF 2
• HIF-1 0
• JAK 0
• GIP 1
• TFEB 0
• YAP 0
• CTNNB1 0
• ERK 0
• COX-2 0
• HSP90 0
• PTEN 0
• STK11 0
• APOE 0
• FTO 0
• HMGB1 0
• IL-6 0
• KEAP1 0
• PCSK9 0
• DPP-4 0
• GPX4 0
• VEGF 0
• FGFR 0
• IL-17 0
• PDGFR 0
• BDNF 0
• IL-1 0
• METTL3 0
• PKM2 0
• TREM2 0
• ACE2 0
• EGFR 0
• FAK 0
• IDH 0
• IDO1 0
• MDM2 0
• PARP 0
• PD-1 0
• RANKL 1
• ABL1 0
• ALK 0
• BCL-2 0
• CD38 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Subcellular Lipid Atlas: Decoding Organelle Identity with Targeted Lipid Profiling (LipID)

  Universitat Wien· Wien, Ausztria· EU contribution 1 500 000 EUR· until 2032. jún.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Metabolic Hepatoprotection to Enable Curative Cancer Therapy in Patients with Vulnerable Livers (SAFE-LIVER)

  Universitaet Bern· Bern, Svájc· EU contribution 150 000 EUR· until 2028. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Epigenomic Liquid Biopsy for Early Detection and Monitoring of Metabolic Dysfunction-Associated Steatohepatitis (cfChIP-MASH)

  The Hebrew University of Jerusalem· Jerusalem, Izrael· EU contribution 150 000 EUR· until 2028. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Crossing borders of liver and adipose tissue (mis)communication: a novel translational approach to study molecular mechanisms and targets in metabolic dysfunction-associated steatotic liver disease (XB-LIVAT)

  Fondazione Italiana Fegato E.t.s.· Trieste, Olaszország· EU contribution 193 643 EUR· until 2028. márc.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploring the impact of Time-Restricted Eating and Exercise interventions on Gut microbiome of patients with hepatic steatosis and obesity – TREEGut

  Universidad de Granada· Granada, Spanyolország· EU contribution 194 075 EUR· until 2027. dec.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Human-based methodologies to study toxicity of food nanoparticles on fatty liver diseases via the microbiota-bile acid axis. (nanoBASH)

  Universite Catholique de Louvain· Louvain la Neuve, Belgium· EU contribution 1 500 000 EUR· until 2030. dec.

• European Commission (Horizon Europe) · HORIZON-ERC

  Fatty liver versus autoimmunity of the bile ducts - defining the gut signals driving steatosis and inflammatory disease of the gut-liver axis (FatVersusBile)

  Universitetet I Oslo· Oslo, Norvégia· EU contribution 2 000 000 EUR· until 2030. ápr.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Defining the role of stromal cells in determining HCC patient response to immunotherapies at single-cell resolution (STRIM-HCC)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spanyolország· EU contribution 194 075 EUR· until 2027. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Scalable target identification for metabolic liver disease (3DMASH)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 1 950 000 EUR· until 2030. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Promoting RObust Systems biology on Patients and Experimental models with obesity-driven liveR cancer (PROSPER)

  Medizinische Universitaet Wien· Wien, Ausztria· EU contribution 183 601 EUR· until 2026. dec.

  The disease is named only in the funder's project summary, not in the title.

10 of 22 running projects, newest first. Listed amounts together: 71,0 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 24
• Organoids 17
• Mendelian Randomization Analysis 45
• CRISPR-Cas Systems 3
• Gene Expression Profiling 105
• Sequence Analysis, RNA 10
• Whole Genome Sequencing 3
• Exome Sequencing 2
• Proteomics 66
• Metabolomics 104
• Mass Spectrometry 10
• Flow Cytometry 3
• Immunohistochemistry 16
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 103
• Machine Learning 103
• Deep Learning 14
• Cohort Studies 172
• Genome-Wide Association Study 49

• Nε-(Carboxymethyl)lysine induces mitochondrial stress, inflammatory activation, and fibrogenic remodelling in multicellular human liver organoids.

  Pharmacol Res, 2026. szept.

• Prime editing models the MTARC1 A165T variant in human liver organoids, demonstrating reduced steatosis, inflammation, and fibrosis.

  Hepatol Commun, 2026. szept.

• A chemically optimized, GalNAc-conjugated siRNA targeting HSD17B13 demonstrates efficacy in a human 3D organoid model of MASH, showcasing an alternative to animal testing.

  PLoS One, 2026. aug.

• MASH Background Confers Enhanced Disease Susceptibility and Acetaminophen Toxicity in iPSC-Derived Liver Organoids.

  Adv Sci (Weinh), 2026. júl.

• Application of Multilineage Human Liver Organoids in Disease Modelling, Drug Testing and Genetic Intervention.

  Liver Int, 2026. júl.

• Hepatoprotective effects of the branched-chain fatty acids 12-methylmyristic and 13-methylmyristic against palmitate-induced lipotoxicity.

  Biomed Pharmacother, 2026. jún.

• S100A10-ANXA2 tetramer inhibition hampers hepatic stellate cell activation in human MASLD organoids.

  EMBO Mol Med, 2026. jún.

• Profiling of extracellular vesicles from primary hepatocytes, organoids, and mash patients identifies cell injury-specific signatures.

  Sci Rep, 2026. jún.

• Organoid models reveal mechanistic connections and sirolimus efficacy in liver-vascular steatosis and foam cell formation.

  Atherosclerosis, 2026. máj.

• New approach methodologies to model liver fibrosis in metabolic dysfunction-associated steatohepatitis.

  BMB Rep, 2026. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.